"Hurdles race for CAR T-cell therapy in digestive tract cancer"

Area of Science:

• Oncology
• Immunotherapy
• Cancer Research

Background:

• Digestive tract cancers (DTC) have high incidence and mortality rates, with pancreatic cancer being particularly challenging.
• Current immunotherapies like immune checkpoint inhibitors (ICI) have limited efficacy in DTC, often requiring combination therapy.
• CAR T-cell therapy has achieved success in hematological malignancies, prompting interest in its application to solid tumors.

Purpose of the Study:

• To review recent advances in preclinical and clinical research of CAR T-cell therapy for digestive tract cancers.
• To identify and discuss the specific challenges and hurdles associated with CAR T-cell therapy in various DTC subtypes.

Main Methods:

• Comprehensive literature review of preclinical studies on CAR T-cell therapy in DTC models.
• Analysis of ongoing and completed clinical trials involving CAR T-cells for digestive tract cancers.
• Evaluation of research addressing the unique tumor microenvironment and antigen targets in different DTCs.

Main Results:

• CAR T-cell therapy demonstrates potential in preclinical models of DTC, with ongoing clinical investigations.
• Challenges include T-cell trafficking, persistence, antigen heterogeneity, and the immunosuppressive tumor microenvironment in DTC.
• Specific subtypes of DTC present unique obstacles and require tailored CAR T-cell strategies.

Conclusions:

• CAR T-cell therapy represents a promising frontier for treating digestive tract cancers, building on successes in blood cancers.
• Overcoming specific hurdles in DTC subtypes is crucial for translating CAR T-cell therapy into effective clinical treatments.
• Further research is needed to optimize CAR T-cell efficacy and safety for patients with digestive tract cancers.